Floatz logo

Omeprazole

Focal Cortical Dysplasia

GRIN Therapeutics, Inc.Small moleculePhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Focal Cortical Dysplasia cohort.

Asset / SponsorPhaseRating
Everolimus
NYU Langone Health
Phase 2B
Radiprodil
GRIN Therapeutics, Inc.
Phase 1/2CCC
svg103
Sovargen
Phase 1/2CCC
Rosuvastatin
GRIN Therapeutics, Inc.
Phase 1CC
MIDAZOLAM
GRIN Therapeutics, Inc.
Phase 1CC

View all 11 →

Same molecule, other indications

Omeprazole is also rated in:

morbid obesityDormant
BB
Indicative ·
70 / 100
View asset →
Helicobacter Pylori InfectionDormant
BB
Indicative ·
68 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →